https://www.selleckchem.com/pr....oducts/Irinotecan-Hc
1, 95% CI 2.9-5.8, P 2× 10 ]. In cancer types that showed no relationship between CD8 T-cell levels and neoantigen load, such as breast cancer, prostate cancer, and glioma, TMB-H tumors failed to achieve a 20% ORR (ORR= 15.3%, 95% CI 9.2-23.4, P= 0.95), and exhibited a significantly lower ORR relative to TMB-L tumors (OR= 0.46, 95% CI 0.24-0.88, P= 0.02). Bulk ORRs were not significantly different between the two categories of tumors (P= 0.1 for patient cohorts assessed. Equivalent results were obtained b
Like
Comment
Share
